Sotrovimab May Prevent Progression to Severe COVID-19
Risk for all-cause hospitalization or death through day 29 reduced with sotrovimab versus placebo for circulating variants at the time of the study
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.